NCT00005937View on ClinicalTrials.gov

Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

June 30, 2000

Primary Completion Date

March 31, 2008

Study Completion Date

March 31, 2008

Conditions
Myelodysplastic Syndrome
Interventions
DRUG

Antithymocyte globulin

Antithymocyte globulin (ATG) intravenous infusion: 40mg/kg/day. Infusion over 6 hours on day 1-4.

DRUG

Cyclosporine

Cyclosporine (CsA) intravenous infusion: 5mg/kg. Infusion on day 14 administered twice a day.

Trial Locations (1)

20892

National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda

All Listed Sponsors
lead

Neal Young, M.D.

NIH

NCT00005937 - Antithymocyte Globulin and Cyclosporine to Treat Myelodysplasia | Biotech Hunter | Biotech Hunter